Between the MERLIN and CASTLE tests for melanoma, which do you prefer and why?

I prefer DecisionDx-Melanoma, without question. It’s the only test that prospectively met its primary endpoint, with SLN positivity below 5% in the low-risk group. Merlin’s CP-GEP did not meet that threshold in MERLIN_001.

DecisionDx also goes beyond the SLNB decision by independently predicting recurrence risk and adding prognostic value beyond AJCC staging. To me, that makes it more useful across the full management pathway, not just for one decision.